#bioverativ

[lucadezzani]

Top Pharma News of the Week

Top Pharma News of the Week

All The Most Important Pharmaceutical News Stories Of The Week – February 2018 – Week #3 US, EU, and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib

  February 12, 2018

Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the company’s New Drug Application for…

View On WordPress

[casorasi]

Bioverativ, Juno and Halliburton rise; Sanmina-SCI tumbles

NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday: Bioverativ, Juno and Halliburton rise; Sanmina-SCI tumbles

[moneyhealthfinance-blog]

Sanofi is buying Bioverativ for $11.6 billion Sanofi's Chief Executive Officer Olivier BrandicourtBenoit Tessier/Reuters French drugmaker Sanofi is acquiring biotech company Bioverativ in a $ 11.6 billion deal. It's the biggest deal f... Business Insider

[moneyhealthfinance-blog]

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS (Reuters) – French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $ 11.6 billion, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases. Sanofi shares fell 3.4 percent by 0920 GMT, making the stock the worst performer on France’s benchmark CAC-40 index and several analysts deemed the deal…

View On WordPress

[stocknewspaper-blog]

"Sanofi shares fall on $11.6 billion Bioverativ takeover" has been added to my site. Please visit for details. http://www.stocknewspaper.com/sanofi-shares-fall-on-11-6-billion-bioverativ-takeover/

[cushydiet-blog]

Sanofi to buy U.S. haemophilia group Bioverativ for $11... - https://wp.me/p8XyML-gFP - #Bioverativ, #Buy, #Group, #Haemophilia, #Sanofi

[moneyhealthfinance-blog]

Healthcare group Sanofi agrees to buy U.S. peer Bioverativ for $11.6 billion

PARIS (Reuters) – French healthcare group Sanofi has agreed to buy U.S. peer Bioverativ for $ 11.6 billion, in a deal which Sanofi said would boost its earnings and strengthen its presence in the field of treatments for rare diseases. Sanofi has agreed to buy all of the outstanding shares of Bioverativ for $ 105 per share in cash, marking a premium of 64 percent to Bioverativ’s closing price on…

View On WordPress

[cushydiet-blog]

Sanofi confirms deal to buy Bioverativ for $11.6 billio... - https://wp.me/p8XyML-gFy - #Billio, #Bioverativ, #Buy, #Confirms, #Deal, #Sanofi